Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
236.5 SEK | -2.91% | -0.17% | +26.04% |
Mar. 15 | Nordic Shares Decreased Friday; BoneSupport Holding Posted Biggest Loss | DJ |
Mar. 14 | Nordic Stocks Moved Upward Thursday; Scatec Climbed Highest | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 122.21 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.04% | 1.47B | D+ | ||
-2.86% | 87.31B | A- | ||
+3.95% | 40.86B | A- | ||
-21.94% | 29.36B | B- | ||
+56.27% | 24.49B | A | ||
-5.41% | 17.31B | C | ||
-44.23% | 11.26B | B | ||
-17.60% | 11.62B | B- | ||
-13.96% | 11.31B | D+ | ||
+6.22% | 8.31B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BONEX Stock
- Ratings Bonesupport Holding AB